Pear Therapeutics (NASDAQ:PEAR – Get Rating) is one of 33 public companies in the “Health services” industry, but how does it contrast to its rivals? We will compare Pear Therapeutics to similar businesses based on the strength of its valuation, dividends, risk, profitability, institutional ownership, analyst recommendations and earnings.
Volatility & Risk
Pear Therapeutics has a beta of 0.93, indicating that its share price is 7% less volatile than the S&P 500. Comparatively, Pear Therapeutics’ rivals have a beta of 1.48, indicating that their average share price is 48% more volatile than the S&P 500.
This table compares Pear Therapeutics and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Pear Therapeutics Competitors||-415.59%||-449.90%||-27.23%|
Earnings and Valuation
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Pear Therapeutics||$4.21 million||-$65.14 million||-8.73|
|Pear Therapeutics Competitors||$1.36 billion||-$98.47 million||30.18|
Pear Therapeutics’ rivals have higher revenue, but lower earnings than Pear Therapeutics. Pear Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
This is a breakdown of current recommendations for Pear Therapeutics and its rivals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Pear Therapeutics Competitors||7||128||274||0||2.65|
Pear Therapeutics presently has a consensus target price of $6.25, indicating a potential upside of 225.52%. As a group, “Health services” companies have a potential upside of 112.74%. Given Pear Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Pear Therapeutics is more favorable than its rivals.
Insider & Institutional Ownership
55.4% of Pear Therapeutics shares are held by institutional investors. Comparatively, 47.2% of shares of all “Health services” companies are held by institutional investors. 30.7% of Pear Therapeutics shares are held by company insiders. Comparatively, 22.1% of shares of all “Health services” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Pear Therapeutics beats its rivals on 8 of the 12 factors compared.
About Pear Therapeutics
Pear Therapeutics, Inc., a commercial-stage healthcare company, develops and sells software-based medicines. Its commercial products are reSET for the treatment of substance use disorder related to alcohol, cannabis, cocaine, and stimulants; reSET-O for the treatment of opioid use disorder in combination with buprenorphine; and Somryst, a software-based treatment for chronic insomnia. The company is also developing a pipeline of 14 product candidates focusing on psychiatry, neurology, and outside of central nervous system therapeutic areas, such as gastrointestinal, oncology, and cardiovascular. Pear Therapeutics, Inc. was incorporated in 2013 and is based in Boston, Massachusetts.
Receive News & Ratings for Pear Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pear Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.